drugset / Trial / NCT07189377

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

NCT07189377

Phase 4 Recruiting 20 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelPrevention

Summary

The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals

Timeline

Start
2025-09-24
Primary completion
2027-08
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 1 mg Oral
Subject hepatitis B immune globulin Protein / enzyme biologic 4500 iu Intravenous